✨ Free AI Report
Delcath Systems, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Delcath Systems, Inc.
Company Research

Delcath Systems, Inc.: Business Overview, Financials & Competitive Analysis

Delcath Systems, Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). Emerging interventional oncology player with validated hepatic delivery technology, growing adoption metrics, and regulatory tailwinds supporting market expansion in liver-directed cancer therapy. Delcath demonstrates solid execution with sustained double-digit volume growth, strong balance sheet ($89.3M cash as of Q1 2026), and expanding clinical validation across multiple cancer indications. Regulatory.

What is Delcath Systems, Inc.'s industry? Delcath Systems, Inc. (delcath.com) operates in Robotic Surgery. AskCyborg classifies Delcath Systems, Inc. under Robotic Surgery in its company registry.

Delcath Systems is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products include HEPZATO KIT and CHEMOSAT Hepatic Delivery System for M...

7/ 10Strong

Cyborg Score thesis

Emerging interventional oncology player with validated hepatic delivery technology, growing adoption metrics, and regulatory...

Read the full analyst-debate transcript →
Industry Robotic Surgery
1 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 21, 2026
AI-Verified Research
30+ Page Report

Get the Latest Delcath Systems, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Delcath Systems, Inc.

AskCyborg analysts argue the bull and bear cases for Delcath Systems, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Delcath Systems, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Delcath Systems, Inc. Overview

Pro stress-test →

Delcath Systems is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products include HEPZATO KIT and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure.

Strategic Profile

Pro stress-test →

The company achieved approximately 30% HEPZATO volume growth in Q2 2026 compared to Q2 2025. In April 2026, CHEMOSAT was included as a recommended liver-directed regional therapy option in the ESMO–EURACAN Clinical Practice Guideline for uveal melanoma, expanding clinical validation and market positioning in oncology.

Competitive Landscape

Pro stress-test →

Sirtex Medical is identified as a competitor in hepatic delivery and regional liver cancer therapy. The interventional oncology space includes other regional therapy platforms and systemic immunotherapy combinations, but Delcath's drug-device combination and proprietary hepatic delivery system provide differentiation in controlling systemic chemotherapy exposure.

Industry Context

Delcath Systems, Inc. operates in Robotic Surgery.

Key facts

Founded: 1988 · Headquarters: Queensbury, NY, US · Revenue: $70.2M trailing twelve-month revenue (as of June 30, 2025) · Market cap: $373M (as of September 2025)

What the analysts stress-tested

The top findings that survived the multi-agent debate for Delcath Systems, Inc..

  • HEPZATO volume grew 30-36% YoY in H1 2026 (Q1: 36%, Q2: 30%), demonstrating strong commercial traction and market acceptance for the company's lead FDA-cleared product.
  • CHEMOSAT inclusion in ESMO–EURACAN uveal melanoma guidelines (April 2026) validates clinical efficacy and positions the company in major treatment algorithms, expanding addressable patient population beyond initial indications.
+1 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • April 2026CHEMOSAT included in ESMO–EURACAN Uveal Melanoma Clinical Practice Guidelines
  • May 2026Q1 2026 earnings announced with 36% HEPZATO volume growth and $70.2M trailing twelve-month revenue
  • +1 moreTrack every material event for Delcath Systems, Inc. as it happens. Explore monitoring →
Get alerted when Delcath Systems, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Sirtex MedicalHepatic regional therapy for liver cancer→

Compare Delcath Systems, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Delcath Systems, Inc. operates in Robotic Surgery. See how the rest of the sector scores on the Cyborg framework.

Browse Robotic Surgery research →
NEW · MCP server

Ask your AI assistant about Delcath Systems, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Delcath Systems, Inc. and its top competitor on Cyborg Score”
“What did Delcath Systems, Inc. do this quarter?”
“Is Delcath Systems, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Delcath Systems, Inc. do?+
Delcath Systems is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products include HEPZATO KIT and CHEMOSAT Hepatic Delivery System for M...
What is Delcath Systems, Inc.'s Cyborg Score?+
Delcath Systems, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Delcath Systems, Inc.'s main competitors?+
Named competitors include Sirtex Medical. The full competitive landscape is in the AskCyborg report.
How can I get the full Delcath Systems, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Delcath Systems, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Delcath Systems, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.